Neurology

FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies

Xembify is a 20% immune globulin solution for subcutaneous injection indicated to treat primary immunodeficiencies in patients aged 2 years and older.
FDA Approvals

Source link




Related posts

UF neurosurgery and neurology departments team up for interdisciplinary NIH grant

Newsemia

Teaching NeuroImages: A child with macrocephaly and psychomotor development delay

Newsemia

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy